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Background
Aspirin reduces the absolute risk of death or dependence
following an acute ischaemic stroke. An associated
increase in risk of haemorrhage may cause considerable
harm. We hypothesised that patients at a high predicted
risk of further thrombosis or a low risk of haemorrhage
would experience greater absolute benefit from aspirin.
In addition we explored the assumption that absolute
benefit increases with baseline risk.
Methods
We applied formal prediction methods to the three
largest randomised trials of aspirin in patients with
acute ischaemic stroke. We developed new prediction
models for early events (14 day thrombosis and haemor-
rhage) and for long term functional outcome (six month
death or dependence) and internally evaluated their per-
formance. We calculated the absolute risk reduction of
death or dependence with aspirin within quarters of pre-
dicted patient risk from early events across trials and
pooled the results using random effects meta-analysis.
Results
Simple prediction models discriminated early events
poorly (AUROCC 0.56 and 0.60) but were moderate at
discriminating long term death or dependence (AUROCC
0.77). There was no evidence of greater benefit or of harm
from aspirin across the sixteen defined subgroups of pre-
dicted risk nor was there any evidence that absolute bene-
fit increased linearly with baseline risk. The best estimate
of the effect of aspirin was the overall absolute risk
reduction of death or dependence of 1% (95%CI: 0% to
2%) in all risk groups.
Conclusions
We found no evidence to support targeting aspirin to
acute ischaemic stroke patients with a high predicted
risk of thrombosis or a low predicted risk of haemor-
rhage. The modest absolute benefit of aspirin was simi-
lar across predicted patient risk of death or dependence.
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